查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年再生障碍性贫血的全球市场
市场调查报告书
商品编码
1140738

2022-2029 年再生障碍性贫血的全球市场

Global Aplastic Anemia Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球血液疾病患者数量的增加正在推动市场增长

再生障碍性贫血是一种当身体不能产生足够的新血细胞时发生的疾病。这种疾病使人容易疲倦，容易出现不受控制的出血和感染。再生障碍性贫血是一种罕见且严重的疾病，可在任何年龄发展。再生障碍性贫血可能会突然发生或随着时间的推移缓慢恶化。再生障碍性贫血可以是中度或严重的。再生障碍性贫血可以通过药物、输血和干细胞移植（也称为骨髓移植）治愈。推动再生障碍性贫血市场增长的主要因素是全球血液病患病率的上升和全球癌症患病率的上升。此外，再生障碍性贫血的技术进步和製药领域研发活动的增加正在为市场增长创造机会。

地理渗透。

北美地区预计将主导全球再生障碍性贫血市场

本研究按地区分析再生障碍性贫血市场，涵盖北美、欧洲、亚太地区、南美、中东和非洲等全球市场。

北美将在 2021 年主导全球再生障碍性贫血市场。预计美国在预测期内将代表北美的大幅增长。由于血液病的高发病率，再生障碍性贫血在美国有望出现增长。预计北美在预测期内的价值也将显着增长。再生障碍性贫血和骨髓疾病患病率的上升预计将推动该地区的市场增长。

在製药行业的增长以及印度和中国的技术进步的推动下，预计亚太地区再生障碍性贫血市场将在预测期内实现快速增长。由于人口增加和慢性病流行，预计亚太地区再生障碍性贫血市场也将增长。

竞争格局。

对全球再生障碍性贫血市场增长做出贡献的主要公司包括拜耳公司、诺华公司、辉瑞公司、Ligand Pharmaceuticals Incorporated、Genezyme Corporation、Mylan N.V.、BIOGEN、OTSUKA Pharmaceutical Co. Ltd.、Regen Biopharma Inc.、BiolinRx和别的。领先公司正在为再生障碍性贫血市场的全球增长采用新产品发布和扩张战略。 2021年8月，辉瑞以54亿美元收购了Global Blood Therapeutics。此次收购加强了公司在稀有血液学领域的影响力。此次收购扩大了辉瑞在镰状细胞病领域领先的专业产品组合和管道，其潜在的全球总销售额峰值超过 30 亿美元。 2020 年 10 月，Rygand 以 4.375 亿美元现金和每股不可转让的业绩费权收购了 Pfenex Inc.，即在实现某些里程碑后获得 7800 万美元现金业绩费的权利。（CVR）完成了收购.此次收购提供了一个有价值的技术平台，以及与领先製药公司在治疗和疫苗方面的付费合作组合。 2022年6月， BioLineRx 宣布与 GenFleet Therapeutics 达成合作研究协议，开发 Motixafortide 治疗胰腺导管腺癌（ PDAC ）。此次合作建立在 Motixafortide 联合抗 PD-1 和化疗作为转移性 PDAC 的二线治疗的 2a 期 COMBAT/KEYNOTE-202 试验的积极最终结果的基础上，以开发这种极具挑战性的疾病 我们将提供强有力的支持为了继续

COVID-19 的影响将对全球再生障碍性贫血市场产生积极影响。

COVID-19 疫情对全球再生障碍性贫血市场的增长产生了积极影响。由于再生障碍性贫血的积极治疗，免疫抑制具有很高的感染和并发症风险，但如果免疫抑制减少炎症组织的晚期破坏将是有益的。因此，COVID-19 大流行推动了 2020 年再生障碍性贫血的市场价值。

全球再生障碍性贫血市场报告提供大约 69 个市场数据表、60 个数字和 170 页结构

目录

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按治疗类型划分的市场细分
  • 按疾病类型划分的市场细分
  • 按管理途径划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 全球血液病患者数量不断增加
      • 癌症患者增加
    • 限制因素
      • 治疗费用高
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型

  • 输血
  • 药物治疗
  • 骨髓输注

第 8 章按疾病类型

  • 获得性再生障碍性贫血
  • 遗传性骨髓衰竭综合征

第 9 章给药途径

  • 静脉给药
  • 口服给药

第 10 章按销售渠道

  • 零售药房
  • 医院药房
  • 在线药店

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 13 章全球再生障碍性贫血市场 - 公司简介

  • 拜耳公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Novartis AG
  • Pfizer Inc.
  • Ligand Pharmceuticals Incorporated
  • Genezyme Corporation
  • Mylan N.V.
  • BIOGEN
  • Otsuka Pharmaceutical Co. Ltd.
  • REGEN BIOPHARMA INC.
  • BiolinRx（*LIST NOT EXHAUSTIVE）

第14章 重要考察

第15章 DataM

简介目录
Product Code: DMPH3135

Market Overview

Aplastic Anemia Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Aplastic anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia, a rare and serious condition, may develop at any age. It can happen suddenly or slowly and worsen over time. It can be either moderate or severe. Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant, may be included in aplastic anemia treatment. The major factors propelling the growth of the aplastic anemia market are the rising number of blood disorder cases worldwide and the rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector are further creating a lucrative opportunity for market growth.

Market Dynamics: Rising number of blood disorder cases worldwide drives the market growth

Aplastic anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia is a rare and serious condition of the body and may develop at any age. Aplastic anemia can happen suddenly or slowly and worsen over time. Aplastic Anemia can be either moderate or severe. Aplastic Anemia is cured by Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The major factors propelling the growth of the aplastic anemia market are the rising number of blood disorder cases worldwide and the rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector are further creating a lucrative opportunity for market growth.

Market Segmentation: The bone marrow transfusion/ stem cell therapy segment is projected to be the dominant segment in the market during the forecast period.

Based on the treatment type, the aplastic anemia market has been classified into bone marrow transfusion/stem cell therapy, blood transfusion and drug therapy.

For decades, hematopoietic stem cell transplantation has been used to treat blood and cardiovascular cell disorders, either unpatched or genetically altered to correct genetic disorders. Also, it is an efficient option for blood disorders with a success rate of over 80%, as per research presented by the American academy of orthopedic surgeons. Thus, rising blood disorders worldwide and efficient usage of stem cells in treating blood disorders are expected to drive the usage of bone marrow transfusion.

Aplastic anemia is segmented based on distribution channel, which includes retail pharmacies, hospitals pharmacies and online pharmacies.

Hospital pharmacies are held a significant market share in the aplastic anemia market. Hospital pharmacies held the dominant position in the global market during the forecast period. A hospital pharmacy is a specialized pharmacy integrated into the medical center's care. These include centers such as a hospital, outpatient clinics, drug-dependent facilities, poison control centers, and a drug information center at a residential care facility. The hospital's pharmacies are expected to gain potential growth in the forthcoming period due to the growing geriatric population and rising number of chronic diseases. Moreover, online pharmacies are expected to project a considerable CAGR during the forecast period. The rising e-commerce sector is expected to propel segment growth in the near future.

Additionally, aplastic anemia is segmented based on disease type, which includes acquired aplastic anemia and inherited bone marrow failure syndromes. Similarly, the route of administration includes intravenous and oral.

Geographical Penetration: North America region is expected to dominate the global aplastic anemia market

Based on geography, the study analyzes the aplastic anemia market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global aplastic anemia market in 2021. The U.S. is expected to represent considerable growth in North America during the forecast period. In the U.S., aplastic anemia is expected to have potential growth owing to the high prevalence rate of blood disorders. Moreover, North America is expected to represent significant growth in terms of value during the forecast period. The rise in the prevalence rate of aplastic anemia and bone marrow disorder is expected to propel market growth across the region.

The aplastic anemia market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of the pharmaceutical industry & technological advancement in India and China. Moreover, the increasing population and increasing prevalence of chronic diseases are expected to augment the growth of the Asia Pacific aplastic anemia market.

Competitive Landscape:

The key aplastic anemia players which are contributing to the growth of the global market include Bayer AG, Novartis AG, Pfizer Inc., Ligand Pharmaceuticals Incorporated, Genezyme Corporation, Mylan N.V., BIOGEN, OTSUKA Pharmaceutical Co. Ltd., Regen Biopharma Inc., and BiolinRx, among others. The major players are adopting new product launches and expansion strategies for global growth in the aplastic anemia market. In August 2021, Pfizer acquired Global Blood Therapeutics for $5.4 Billion. This acquisition enhances the company's presence in Rare Hematology. This acquisition expands the leading sickle cell disease expertise portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion. In October 2020, Ligand completed the acquisition of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share, representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved. This acquisition provides a valuable technology platform and portfolio of royalty-bearing collaborations with leading pharmaceutical companies for treatments and vaccines. In June 2022, BioLineRx announced a collaboration agreement with GenFleet Therapeutics to develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC). This collaboration is based on positive final results from Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with anti-PD-1 and chemotherapy as second-line metastatic PDAC therapy, which provides strong support for continued development in this very challenging disease.

COVID-19 Impact: Positive impact on the global aplastic anemia market.

The outbreak of COVID-19 has positively impacted the growth of the aplastic anemia market globally. Since people receive active treatment for aplastic anemia, immunosuppression involves a higher risk of infection and complications; however, it may be beneficial if immunosuppression reduces the late destruction of hyperinflammatory tissue. Therefore, the COVID-19 pandemic drove the market value of the aplastic anemia market in 2020.

The global aplastic anemia market report would provide an access to approximately 69 market data tables, 60 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Treatment Type
  • 3.2. Market Snippet by Disease Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising number of blood disorder cases across the world
      • 4.1.1.2. Rising number of cancer patients
    • 4.1.2. Restraint
      • 4.1.2.1. High cost of treatment
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
  • 7.3. Market Attractiveness Index, By Treatment Type Segment
    • 7.3.1. Blood transfusion
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Drug therapy
    • 7.3.3. Bone Marrow Transfusion

8. By Diseases Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 8.3. Market Attractiveness Index, By Diseases Type Segment
    • 8.3.1. Acquired aplastic anemia
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Inherited bone marrow failure syndromes

9. By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Intravenous
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Oral

10. By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Retail pharmacies
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Hospital pharmacies
    • 10.3.3. Online pharmacies

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Aplastic Anemia Market- Company Profiles

  • 13.1. Bayer AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Novartis AG
  • 13.3. Pfizer Inc.
  • 13.4. Ligand Pharmceuticals Incorporated
  • 13.5. Genezyme Corporation
  • 13.6. Mylan N.V.
  • 13.7. BIOGEN
  • 13.8. Otsuka Pharmaceutical Co. Ltd.
  • 13.9. REGEN BIOPHARMA INC.
  • 13.10. BiolinRx (*LIST NOT EXHAUSTIVE)

14. Premium Insights

15. DataM Intelligence Analysis

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us